Developing antibody therapeutics for T cell-acute lymphoblastic leukemia (T-ALL)
Despite successes in developing effective immunotherapy for B-ALL, little progress has been made for T-ALL. New targets which distinguish T-ALL blasts and normal T lymphocytes need to be identified and novel immunotherapy agents developed for this type of ALL.
My previous work includes high molecular weight polyethylene glycol (PEG) and anti-PEG antibodies in hypersensitivity reactions to pegaspargase, liposome-conjugated PEG, and unconjugated PEG; pegaspargase pharmacokinetics; age-dependent hepatotoxicity of pegaspargase; pharmacogenomics of chemotherapy-induced toxicity in pediatric leukemia.
Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, et al. Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. J Clin Oncol. 2019;37(23):2051-61.
Liu Y, Panetta JC, Yang W, Karol SE, Cheng C, Yang JJ, et al. Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood. 2020;136(25):2955-8.
Stone CA, Jr., Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized. J Allergy Clin Immunol Pract. 2019;7(5):1533-40 e8.